Montelukast sodium/Montelukast + levocetirizine dihydrochloride
Montemune containing Montelukast is an oral drug, which is used for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
Montemune-LC contains Montelukast with Levocetirizine. Levocetirizine is a third generation, non-sedating, selective histamine H1 receptor antagonist, with antihistamine, anti-inflammatory and potential anti-angiogenic activities. Levocetirizine competes with endogenous histamine for binding at peripheral H1-receptor sites on the effector cell surface. This prevents the negative symptoms associated with histamine release and an allergic reaction.
Montelukast sodium 10mg/Montelukast sodium 10mg+ levocetirizine
MODE OF ACTION:
Montelukast (empirical formula C35H35ClNNaO3S) is a highly selective leukotriene receptor antagonist that binds with high affinity to the cysteinyl leukotriene receptor for leukotrienes D4 and E4. These leukotrienes are excreted by various types of cells, such as mast cells, and are involved in the inflammatory process that may cause the signs and symptoms of asthma and allergic rhinitis. Leukotriene receptors are found in airway cells, such as macrophages and smooth muscle cells. When bound to leukotriene receptors, montelukast inhibits leukotriene physiologic effects (such as airway edema, smooth muscle contraction, and impairment of normal cellular activity) without exhibiting any agonist activity.
Levocetirizine works by blocking histamine receptors. It does not prevent the actual release of histamine from mast cells, but prevents it binding to its receptors.
- Chronic asthma
- Seasonal allergy
- Perennial allergy
- Allergic rhinitis
Once a day
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.